跳至主要内容
临床试验/NL-OMON24472
NL-OMON24472已完成不适用

Prevention of (re)hospitalisation for heart failure and/or mortality by an intensive, protocolised intervention by both a clinician and a cardiovascular nurse in a country with a primary care-based health care system. system ( the Netherlands).

Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.0 个研究点目标入组 240 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
240

研究概览

简要总结

Bruggink-Andre de la Porte PW, Lok DJ, van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen DJ, Hoes AW. Related Articles, Links.
Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study.
Eur J Heart Fail. 2005 Aug;7(5):910-20. Review.
PMID: 16087143 [PubMed - indexed for MEDLINE].

研究设计

研究类型
Interventional

入排标准

入选标准

  • The following are required at screening visit:
  • 1. In – or out hospital patients with congestive heart failure New York Heart Association Functional Class III and IV;

排除标准

  • 1. Severe dementia or serious psychiatric illness;
  • 2. Discharge to a nursing home;

研究者

发起方
Funding/Support: This study was financially supported by a grant from Novartis Pharma BV, AstraZeneca BV, Bristol-Myers Squibb BV. Roche Diagnostics provided the test essays for NT-proBNP.Role of sponsors: The funding source for this study played no role in the design or conduct of the study; data management and analysis; or manuscript preparation, review, and authorisation for submission.

相似试验